Pain is an unpleasant sensory and emotional experience related to actual or potential tissue damage (Pain, 1979). Mood disorders such as depression and anxiety disorder are commonly developed in people suffering from chronic pain, which is shown in multiple epidemiological studies (Tsang et al., 2008; Hilderink et al., 2012; Velly and Mohi, 2018). The burden of pain and anxiety is high from physiological, psychological, and societal perspectives. Moreover, a study indicated that pain in multiple locations is more likely to develop the first onset of anxiety disorder (Gerrits et al., 2014). Overall, treatment strategies containing both analgesic and anxiolytic effects should be established for patients with chronic pain.
Consequently, preclinical studies focused on such issues. They managed to develop anxiety-like behavior in mice with persistent inflammatory or neuropathic pain induced by the injection of complete Freund’s adjuvant (CFA) or by spared nerve injury (SNI) (Sellmeijer et al., 2018; Liang et al., 2020). Furthermore, brain regions and neural circuits related to pain-induced anxiety have been studied, among which the most frequently mentioned is the anterior cingulate cortex (ACC) (Zhuo, 2016). Clinically, the imaging study showed the involvement of ACC in pain processing, and preclinical evidence demonstrated that the activation of ACC neurons is associated with pain-like behavior. In contrast, the inhibition of these neurons attenuated such behavior (Barthas et al., 2015). As for pain-induced anxiety, presynaptic long-term potentiation (pre-LTP) in ACC was found in mice with chronic pain-induced stress, while eliminating it had an anxiolytic effect in CFA and SNI models (Koga et al., 2015). Another study also discovered ACC hyperactivity in chronic pain-induced anxiety, more shown explicitly by the increased excitatory postsynaptic transmission and increased involvement of N-methyl-D-aspartate (NMDA) receptors (Sellmeijer et al., 2018). These results suggested not only vital role of ACC in pain-induced anxiety but also shed light on a potential therapeutic target of a particular medicine.
As a first-line of treatment for generalized anxiety disorder, duloxetine, one of the serotonin–norepinephrine reuptake inhibitors (SNRIs), has displayed its potential in alleviating chronic pain and pain-induced anxiety (Lunn et al., 2014). However, the mechanisms of effects of duloxetine on both symptoms remain unclear, hindering the broader usage of this drug. Serotonin is related to anxiety disorder and chronic pain (Marcinkiewcz et al., 2016; Paredes et al., 2019). The excitability of glutamatergic neurons in ACC is significantly reduced after the local injection of serotonin, and such reduction can be reversed by a 5-HT1A receptor antagonist (Tian et al., 2017). Above all, it is essential to verify the potential therapeutic effect of duloxetine on chronic pain-induced anxiety and its mechanism by upregulating the 5-HT1A receptor and thus reducing the excitability of glutamatergic neurons.
In this study, we discovered the intraperitoneal effect of duloxetine on anxiety and pain in mice with chronic inflammatory pain through behavioral tests on mechanical hyperalgesia and anxiety-like behaviors. As an assumptive target region, we locally injected duloxetine into ACC to confirm whether duloxetine acts through this certain brain region. Additionally, we used fiber photometry to measure the effect of duloxetine on the activity of glutamatergic neurons and the concentration of serotonin in ACC.
Materials and methods
Animals and groups
Our experiments were performed under the approval of the IACUC at ShanghaiTech University. C57BL/6J male mice (Vital River Shanghai China) aged 8–10 weeks were utilized in all experiments. Mice were housed up to five per cage with free access to food and water and maintained a 12 h light/dark cycle (lights on from 7 a.m. to 7 p.m.) at a stable temperature ranging from 22 to 25°C. Throughout the whole experiment, 90 mice were used in total.
In fiber photometry test, after the injection of rAAV-CaMKIIa-GCamp6s or rAAV-hSyn-5HT3.5 and a 14-day recovery, C57BL/6J male mice were divided into two groups: duloxetine and saline, where duloxetine group received intraperitoneal duloxetine injection. In contrast, the saline group received an intraperitoneal saline injection (Table 1).
In systemic duloxetine injection, mice that underwent CFA injection in the left hind paw are defined as the CFA group, while the mice receiving a saline injection in the left hind paw are defined as the SHAM group. After the modeling and baseline behavioral tests, CFA mice were divided into two groups: the duloxetine group and the saline group, where they received their corresponding intraperitoneal injections for 3 days (Table 1).
In ACC local infusion, similar to the grouping logic in systemic duloxetine injection, mice were divided into CFA and SHAM groups after CFA and saline injections in the left hind paw. CFA mice are divided into duloxetine and vehicle groups; the duloxetine group received intracerebral duloxetine [dissolved in 10% dimethyl sulfoxide (DMSO)] injection, while the vehicle group received intracerebral 10% DMSO (Table 1).
Inflammatory pain model
Inflammatory pain was induced by the injection of CFA (20 μl) into the left hind paw of the mouse (Wang et al., 2015; Zhu et al., 2021). Matched amount of saline was injected into the same place as the SHAM group. On the 12th day after the first injection, the second dose of CFA/saline was injected into the same site to prolong the effect of the model (Jin et al., 2020).
Von Frey filament test
The mechanical withdrawal threshold was measured by the von Frey filament (Stoelting America, Illinois, IL, USA) using an up-down method (Chaplan et al., 1994). Mice were placed on an elevated metal mesh board and under the cover of transparent plastic chambers (9 cm × 9 cm × 4.5 cm). This test was only performed in the light cycle. Before the sequencing tests, the mice should be habituated for 3 days. On the first day of habituation, the mice were put on the board until they fell asleep (about 60–90 min), while on the next 2 days, they were applied two rounds of filament (1 g) probing to the left hind paw (where CFA was injected). During the formal tests, von Frey filaments (bending force ranging from 0.008 to 1.4 g) were applied five times (3 s for each stimulus) to the test site mentioned above. Sudden paw withdrawal and paw licking were considered positive responses. The smallest bending force of the von Frey filament that evokes positive responses with over 50% occurrence frequency is regarded as the mechanical threshold of the mice.
Elevated plus maze test
Anxiety-like behavior was tested by the elevated plus maze test (EPM) with a generally identical procedure to the previous study (Ni et al., 2022). Mice were placed in a cross-shaped, elevated maze with an open arm and a closed arm (50 cm above the ground, open arm: 27 cm × 7 cm; close arm: 27 cm 7 cm × 15 cm). They were placed on the central platform facing the open arm, and their behavior was recorded for 300 s. The time spent in the open arm (the time of mice sticking at least half of their body out of the open arm is considered in the open arm) was collected. The result was presented as the ratio of time in the open arm to time in the closed arm.
Novelty-suppressed feeding test
The anxiodepressive-like behavior was confirmed by the novelty-suppressed feeding test (NSF) (Marcinkiewcz et al., 2016). The testing apparatus of NSF consists of an open field box (25 cm × 25 cm × 25 cm) covered with the identical bedding used in the home cage. A piece of fruit loops (Kellogg’s, Michigan, MICH, USA) was placed on a circular white filter paper in the middle of the open field. After 24 h of being singly caged and food deprivation, the mice were placed in the corner of the open field. The latency to have the first bite of the food was recorded, up to 10 min. After the test, the mice were moved back to the home cage with free access to the fruit loops to measure the food intake for 5 min. The weight before and after home cage feeding was recorded.
Duloxetine (SNRIs, duloxetine hydrochloride enteric capsules, Cymbalta ® Eli Lilly; Beyotime Biotechnology, Shanghai, China) was dissolved in 0.9% saline or 10% DMSO in different concentrations as follows: 20 mg/kg for intraperitoneal injection (i.p.) and 0.25 ml of duloxetine was injected; 200 mg/kg for intracerebral injection (i.c.) and 1 μl of duloxetine was injected. During behavioral tests, duloxetine was given around 1 p.m. for 3 days.
rAAV-CaMKIIa-GCamp6s (≥ 5.00E + 12 vg/ml) and rAAV-hSyn-5HT3.5 (≥ 5.00E + 12 vg/ml) were purchased from BrainVTA (Wuhan, China). Optical fiber and cannulae were purchased from RWD Life Science Co., LTD., (Shenzhen, China). The procedures were generally identical to the previous study (Li et al., 2020). Mice were anesthetized with isoflurane (4% for induction and 1.5% for maintenance). Then, they were placed in a stereotactic apparatus to adjust the skulls parallel to the reference panel. A total of 200 nl of the virus were injected into unilateral ACC gradually in 5 min (Bregma: −0.97 mmAP, ±0.25 mmML, −1.5 mmDV) (Paxinos and Franklin, 2019) by using a micro syringe injector followed by a 10-min interval for viral particle diffusion before planting the optical fiber to the target site (Bregma: −0.97 mmAP, ±0.25 mmML, −1.3 mmDV). The cannula implantation steps were identical to what was mentioned, excluding the AAV injection process.
After 2 weeks of recovery, the mice were ready for the Ca2+ signal recording procedure. The procedure was generally identical to previous studies (Li et al., 2020; Zhu et al., 2021). In brief, Ca2+ signals were obtained from a fiber photometry system. The analog voltage signals were digitalized at 100 Hz and were recorded by a Power 1401 digitizer and Spike2 software (CED, Cambridge, UK). The laser power was adjusted to 20–40 μW. The data we retrieved were exported to MATLAB R2020a mat files (The MathWorks, Massachusetts, MA, USA). The first step was to correct the bleaching of the signal. An approximately 300-s-long section from the incipient and ending stage was selected to fit a curve through these two phases. We derived the values of Ca2+ signal changes (ΔF/F) by calculating (F–F0)/F0, which were presented with average plots with several curves representing the signal changes. Specifically, F0 represents the mean of the signal during a 500 s baseline. To obtain the value for statistics, the mean of ΔF/F values 300 s before drug injection is calculated as the control value and the mean of ΔF/F values during the first 3,500 s after injection as the treatment value.
The instrument and procedure of neurotransmitter sensor recording resemble Ca2+ signal recording. The only difference is that we obtained the mean of ΔF/F values during the first 5,000 s after injection as the treatment value.
The mice were anesthetized by the intraperitoneal injection of tribromoethanol (mass fraction: 2.5%, i.p.) followed by saline perfusion through the heart and then fixation by 4% paraformaldehyde (PFA) after blood was drained. The brain was removed the next day and transferred to 30% sucrose in 0.1 M PBS, pH 7.4, for 24 h. We used cryostat (Leica CM3050S) to obtain coronal sections (40 μm). The slides were washed with 0.1 M PBS, pH 7.4. We performed 4’,6-diamidine-2-phenylindole (DAPI) staining to identify the cell bodies and 10% of glycerin to seal the slides. Fluorescent images were scanned via an Olympus VS 120 microscope.
All statistical analyses were completed in GraphPad Prism 9 (GraphPad Software, California, CA, USA) or MATLAB R2020b programs (The MathWorks, Massachusetts, MA, USA). We used paired or unpaired t-tests for different needs accordingly. Mann–Whitney test was used if the data had significantly different variances. Differences between groups were judged to be statistically significant when p-values is < 0.05. Asterisks denote statistical significance *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Duloxetine increases serotonin concentration while deactivating glutamatergic neurons in anterior cingulate cortex
To discover the target region of duloxetine and its underlying mechanism, we planted optic fiber after injecting rAAV-CaMKIIa-Gcamp6s into either the right or left ACC of C57BL/6J male mice to measure the activity of glutamatergic neurons. We also injected rAAV-hSyn-5HT3.5 into the same site of another batch of mice to measure local serotonin levels (Figures 1A,B,E).
Figure 1. Duloxetine increases serotonin concentration while deactivating glutamatergic neurons in anterior cingulate cortex (ACC). (A) Schematic diagram of the experimental procedure for fiber photometry of 5-HT sensor fluorescence signals and Ca2+ signal recording of CaMKIIa-Gcamp6s of mice ACC. (B) Image of CaMKIIa-Gcamp6s and the fiber channel in ACC. (C) Fluorescence changes of CaMKIIa-Gcamp6s in ACC after the intraperitoneal injection of duloxetine. (D) Average ΔF/F after saline and duloxetine injection (Duloxetine n = 5, saline n = 4, p = 0.0434, unpaired t-test). (E) Image of the 5-HT sensor and the fiber channel in ACC. (F) Fluorescence changes of the 5-HT sensor in ACC after the intraperitoneal injection of duloxetine. (G) Average ΔF/F after saline and duloxetine injection (n = 4, p = 0.0083, unpaired t-test).
We found that duloxetine had increased serotonin concentration in ACC compared with saline (n = 4, p = 0.0083, unpaired t-test; Figures 1F,G) based on the data recorded by fiber photometry, while it decreased the activity of glutamatergic neurons (duloxetine n = 5, saline n = 4, p = 0.0434, unpaired t-test; Figures 1C,D) based on the result of Ca2+ signal recording.
Systemic duloxetine improved mechanical withdrawal threshold and anxiety-like behaviors in mice with chronic inflammatory pain
To examine duloxetine’s therapeutic effect on pain-induced anxiety, we used CFA (saline was injected in the SHAM group) model to induce inflammatory pain in mice. We replenished another injection on day 12 from the first shot to maintain the algetic effect (Figure 2A). We used von Frey filament to measure the mechanical withdrawal threshold at baseline, days 1, 5, 10, 15, and 20 to ensure that CFA mice have a significantly lower mechanical withdrawal threshold than the SHAM group (CFA: n = 24, SHAM: n = 12 baseline p = 0.4690 days 1–20: p < 0.0001, Mann–Whitney test; Figure 2B). On days 21 and 22, EPM tests were used to identify the CFA mice that have successfully induced anxiety-like behaviors. The result indicated that mice expressed anxiety-like behaviors 21 days after CFA injection. To be specific, CFA mice spent significantly less time in the open arm in the EPM test (CFA: n = 18, SHAM: n = 12, p = 0.0023, unpaired t-test; Figure 2C), while the latency to feed is significantly longer than the SHAM group (CFA: n = 18, SHAM: n = 9, p = 0.0002, unpaired t-test; Figures 2D,E).
Figure 2. Mice showed anxiety-like behavior after the chronic inflammatory pain model. (A) Timeline of CFA injection and subsequent behavioral tests. (B) Withdrawal threshold of CFA and SHAM groups during the modeling process (CFA: n = 24, SHAM: n = 12 baseline p = 0.4690 days 1–20: p < 0.0001, Mann–Whitney test). (C) The ratio of time in the open arm and time in the closed arm of CFA and SHAM groups 21 days after the first CFA injection (CFA: n = 18, SHAM: n = 12, p = 0.0023, unpaired t-test). (D) Latency to feed of CFA and SHAM groups (CFA: n = 18, SHAM: n = 9, p = 0.0002, unpaired t-test). (E) Quantity of food consumed in home cage feeding test (CFA: n = 18, SHAM n = 9, p = 0.5408, unpaired t-test).
After the baseline behavior tests, mice with anxiety-like behavior were selected and divided into two groups: the duloxetine group and the saline group. The duloxetine group received duloxetine (20 mg/kg, i.p.) for 3 days, while saline was injected into the saline group (Figures 3A,B). Then, identical tests were performed to measure the therapeutic effect of duloxetine. Von Frey filament showed that the mechanical withdrawal threshold of the duloxetine group is significantly higher than the saline group (n = 9, p = 0.0029, Mann–Whitney test; Figure 3C). In the EPM test, the duloxetine group spent significantly more time in the open arm (n = 9, p = 0.0012, unpaired t-test; Figure 3D), while the latency to feed was significantly shorter than the saline group in the NSF test (n = 9, p = 0.0004, unpaired t-test; Figures 3E,F). Systemic duloxetine improved mechanical withdrawal threshold and anxiety-like behaviors in mice with chronic inflammatory pain.
Figure 3. Systemic duloxetine improved mechanical withdrawal threshold and anxiety-like behaviors in mice with chronic inflammatory pain. (A) Timeline of duloxetine injection and subsequent behavioral tests. (B) Intraperitoneal injection of duloxetine. (C) Withdrawal threshold of duloxetine and saline group after a 3-day injection (n = 9, p = 0.0012, unpaired t-test). (D) The ratio of time in the open arm to closed arm of duloxetine and saline groups (n = 9, p = 0.0012, unpaired t-test). (E) Latency to feed of duloxetine and saline groups (n = 9, p = 0.0004, unpaired t-test). (F) Quantity of consumed food in home cage feeding test (n = 9, p = 0.7751 unpaired t-test).
Intra-anterior cingulate cortex duloxetine improved mechanical withdrawal threshold but did not affect anxiety-like behaviors in mice with chronic inflammatory pain
We planted cannulae in bilateral ACC in mice (Figures 4B,C) and used identical procedures of modeling and screening (Figure 4A). We picked CFA (Figure 4D) mice that have successfully induced anxiety-like behaviors (EPM: CFA: n = 12, SHAM: n = 5, p = 0.0131, unpaired t-test; Figure 4F; NSF: CFA: n = 12, SHAM: n = 5, p = 0.0290, unpaired t-test; Figures 4H,I) and divided into duloxetine and vehicle groups. Like systemic injection, we consecutively injected duloxetine (10% DMSO for the vehicle group) for 3 days before using behavior tests to determine the effect of local infusion in ACC. We found out that the mechanical withdrawal threshold of duloxetine was significantly higher than those of the saline group (n = 6, p = 0.0087, Mann–Whitney test; Figure 4E). However, the EPM test (n = 6, p = 0.7064, unpaired t-test; Figure 4G) and the NSF test (n = 6, p = 0.8291, unpaired t-test; Figures 4J,K) showed no difference between the two groups. In conclusion, intra-ACC duloxetine improved the mechanical withdrawal threshold but did not affect anxiety-like behaviors in mice with chronic inflammatory pain.
Figure 4. Intra-anterior cingulate cortex (ACC) duloxetine improved mechanical withdrawal threshold but had no effect on anxiety-like behaviors in mice with chronic inflammatory pain. (A) Timeline of cannula implantation, CFA injection, behavioral tests, and drug infusion. (B) Cannula implantation and local infusion. (C) Representative brain slice of cannulae implantation in ACC. (D) Withdrawal threshold of CFA and SHAM groups during the modeling process (CFA: n = 26, SHAM: n = 5 baseline p = 0.7398 days 1–20: p < 0.0001, Mann–Whitney test). (E) Withdrawal threshold of duloxetine and saline group after a 3-day local infusion (n = 6, p = 0.0087, Mann–Whitney test). (F) The ratio of time in the open arm and time in the closed arm of CFA and SHAM groups 21 days after the first CFA injection (CFA: n = 12, SHAM: n = 5, p = 0.0131, unpaired t-test). (G) The ratio of time in the open arm and time in the close arm of duloxetine and vehicle groups after local infusion (n = 6, p = 0.7064, unpaired t-test). (H) Latency to feed of CFA and SHAM groups (CFA: n = 12, SHAM: n = 5, p = 0.0290, unpaired t-test) and (I) quantity of food consumed in a home cage feeding test 21 days after the first CFA injection (CFA: n = 12, SHAM n = 5, p = 0.8291, unpaired t-test). (J) Latency to feed of duloxetine and vehicle group (n = 6, p = 0.7020, unpaired t-test) and (K) quantity of food consumed in home cage feeding test after a 3-day local infusion (n = 6, p = 0.8387, unpaired t-test).
In this study, we discovered the analgesic and anxiolytic effects of duloxetine in mice with chronic inflammatory pain-induced anxiety. Second, we found the analgesic but not the anxiolytic effect of duloxetine when locally injected into ACC. Furthermore, we unveiled that duloxetine increased serotonin concentration while decreasing the activity of glutamatergic neurons in ACC.
Duloxetine and other SNRIs are considered the first-line therapeutic in clinical practice for neuropathic pain (Finnerup et al., 2015). Besides, it is also one of the antidepressants used to treat generalized anxiety disorder (Kupfer et al., 2012; Slee et al., 2019). Based on these two therapeutic effects of duloxetine, we took an assumption. We verified that it has analgesic and anxiolytic effects in chronic pain-induced anxiety by the systemic injection of duloxetine in CFA mice. Ito et al. (2018) have found that duloxetine attenuated the mechanical hyperalgesia induced by spinal nerve ligation which coincided with our finding. However, the model we used, CFA, is not a typical neuropathic pain model but an inflammatory pain. The fact that duloxetine could alleviate inflammatory pain is an inspiration that duloxetine could facilitate the treatment of not only neuropathic pain but other categories of them. There were clinical trials of duloxetine’s pain reduction effect in knee osteoarthritis (Frakes et al., 2011; Enteshari-Moghaddam et al., 2019). Above all, duloxetine showed a promising potential to alleviate not only neuropathic pain but also inflammatory pain.
Although duloxetine is clinically used for treating pain, the mechanism of its analgesic effect remains unclear. Through our discoveries, we could first glance at its target brain region and its modulation properties with different neurotransmitters. First, we chose ACC as a potential target due to its reported connection and role in pain, stress, and chronic pain-induced anxiety (Shackman et al., 2011; Bliss et al., 2016). The current study did not verify that duloxetine could upregulate 5-HT1A receptors in ACC; therefore, more research is needed to confirm. However, as one of the SNRIs, it indeed increases the serotonin concentration in ACC to inhibit the activity of glutamatergic neurons, as is proved by our fiber photometry result. In addition, intra-ACC injection of duloxetine attenuated the mechanic withdrawal threshold in CFA mice. These results could verify our previous assumption on the mechanism of duloxetine in ACC with the help of the findings from other studies mentioned in our section “Introduction” (Marcinkiewcz et al., 2016; Tian et al., 2017; Paredes et al., 2019).
Furthermore, our data revealed that the intra-ACC injection of duloxetine could not alleviate the anxiety-like behaviors in CFA mice, whereas systemic duloxetine could alleviate, suggesting that ACC is not the target brain region for duloxetine’s anxiolytic effect. However, ACC still play a vital role in chronic pain-induced anxiety. Still, it urges that the anxiolytic effect of duloxetine is due to its interaction with certain neurotransmitters or receptors in other brain regions that are possibly upstream or downstream of a neuronal circuit involving ACC. Zhuo (2016) has proposed that ACC may act as a higher structure that integrates anxiety signaling through the projection from the amygdala, which is also involved in anxiety and fear. Therefore, further studies should focus on anxiolytic effect of duloxetine and potential mechanism in the amygdala. Last, Barthas et al. (2015) found that repeated optogenetic stimulation in pyramidal neurons in ACC induced anxiodepressive-like behaviors in mice. Besides, the ablation of ACC after the chronic pain model could prevent the anxiodepressive-like behavior taken 6 weeks after surgery. Such results coincided with our theory above and provided us with a potential usage of duloxetine which could inhibit the glutamatergic activity in ACC. The early intervention of duloxetine might prevent the induction of anxiety due to chronic pain. This assumption, along with the potential anxiolytic mechanism of duloxetine, is the future direction.
Limitations and future directions
This study only used duloxetine with fixed concentration, and we only tested the mechanical allodynia. The behavioral test for heat hyperalgesia is missed. Besides, we did not locate the brain region where duloxetine could achieve its anxiolytic effect. Therefore, we intended to study further the anxiolytic effect of duloxetine and its mechanism in mice with chronic pain-induced anxiety.
We used DMSO as the vehicle for duloxetine in local infusion into ACC. It is reported in previous studies that the intraperitoneal injection of 10% DMSO led to significant motor impairment (Matias et al., 2018). Furthermore, another study discovered that local infusion to dorsal periaqueductal gray could increase the exploratory activity in the EPM test (Matheus et al., 1997). Further verification should be done to rule out the potential interference of DMSO which might cause the result in our study.
This study revealed the analgesic and anxiolytic effects of duloxetine in mice with chronic inflammatory pain. However, duloxetine lost its anxiolytic effect when locally injected into ACC. Moreover, we unveiled that duloxetine increased serotonin concentration while decreasing the activity of glutamatergic neurons in ACC.
Data availability statement
The original contributions presented in this study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.
This animal study was reviewed and approved by the ShanghaiTech University.
CL designed the study, conducted the experiments, analyzed the data, and wrote the article. KN analyzed the data and revised the article. MQ and KY assisted in part of the behavioral tests. JL and YL helped to design the study and revised the article. All authors contributed to the article and approved the submitted version.
This current study was funded by the Shanghai Hospital Development Center (Grant Number: SHDC2020CR6023), the Shanghai Hospital Development Center (Grant Number: SHDC2020CR1027B), Shanghai Clinical Research Center for Mental Health (19MC1911100), and the grants from Shanghai Municipal Health Commission (2019ZB0201).
We express our earnest gratitude toward Professor Ji Hu of ShanghaiTech University and members of Hu Lab for their professional support. We also thank the members of the Molecular Imaging Core Facility and Molecular and Cellular Biology Core Facility at ShanghaiTech University for their generous help.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
ACC, anterior cingulate cortex; CFA, complete Freund’s adjuvant; pre-LTP, presynaptic long-term potentiation; DMSO, dimethyl sulfoxide; EPM, elevated plus maze test; NMDA, N-methyl-D-aspartate; NSF, novelty-suppressed feeding test; PFA, paraformaldehyde; SNI, spared nerve injury; SNRIs, serotonin–norepinephrine reuptake inhibitors.
Barthas, F., Sellmeijer, J., Hugel, S., Waltisperger, E., Barrot, M., and Yalcin, I. (2015). The anterior cingulate cortex is a critical hub for pain-induced depression. Biol. Psychiatry 77, 236–245. doi: 10.1016/j.biopsych.2014.08.004
Bliss, T. V., Collingridge, G. L., Kaang, B. K., and Zhuo, M. (2016). Synaptic plasticity in the anterior cingulate cortex in acute and chronic pain. Nat. Rev. Neurosci. 17, 485–496. doi: 10.1038/nrn.2016.68
Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M., and Yaksh, T. L. (1994). Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 53, 55–63. doi: 10.1016/0165-0270(94)90144-9
Enteshari-Moghaddam, A., Azami, A., Isazadehfar, K., Mohebbi, H., Habibzadeh, A., and Jahanpanah, P. (2019). Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis. Clin. Rheumatol. 38, 2873–2880. doi: 10.1007/s10067-019-04573-7
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., et al. (2015). Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 14, 162–173.
Frakes, E. P., Risser, R. C., Ball, T. D., Hochberg, M. C., and Wohlreich, M. M. (2011). Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr. Med. Res. Opin. 27, 2361–2372. doi: 10.1185/03007995.2011.633502
Gerrits, M. M. J. G., van Oppen, P., van Marwijk, H. W. J., Penninx, B. W. J. H., and van der Horst, H. E. (2014). Pain and the onset of depressive and anxiety disorders. Pain 155, 53–59. doi: 10.1016/j.pain.2013.09.005
Hilderink, P. H., Burger, H., Deeg, D. J., Beekman, A. T., and Oude Voshaar, R. C. (2012). The temporal relation between pain and depression: results from the longitudinal aging study Amsterdam. Psychosom. Med. 74, 945–951. doi: 10.1097/PSY.0b013e3182733fdd
Ito, S., Suto, T., Saito, S., and Obata, H. (2018). Repeated administration of duloxetine suppresses neuropathic pain by accumulating effects of noradrenaline in the spinal cord. Anesth. Analg. 126, 298–307. doi: 10.1213/ANE.0000000000002380
Jin, Y., Meng, Q., Mei, L., Zhou, W., Zhu, X., Mao, Y., et al. (2020). A somatosensory cortex input to the caudal dorsolateral striatum controls comorbid anxiety in persistent pain. Pain 161, 416–428. doi: 10.1097/j.pain.0000000000001724
Koga, K., Descalzi, G., Chen, T., Ko, H. G., Lu, J., Li, S., et al. (2015). Coexistence of two forms of LTP in ACC provides a synaptic mechanism for the interactions between anxiety and chronic pain. Neuron 85, 377–389. doi: 10.1016/j.neuron.2014.12.021
Kupfer, D. J., Frank, E., and Phillips, M. L. (2012). Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 379, 1045–1055. doi: 10.1016/S0140-6736(11)60602-8
Li, J., Lu, C., Gao, Z., Feng, Y., Luo, H., Lu, T., et al. (2020). SNRIs achieve faster antidepressant effects than SSRIs by elevating the concentrations of dopamine in the forebrain. Neuropharmacology 177:108237. doi: 10.1016/j.neuropharm.2020.108237
Liang, H. Y., Chen, Z. J., Xiao, H., Lin, Y. H., Hu, Y. Y., Chang, L., et al. (2020). nNOS-expressing neurons in the vmPFC transform pPVT-derived chronic pain signals into anxiety behaviors. Nat. Commun. 11:2501. doi: 10.1038/s41467-020-16198-5
Lunn, M. P., Hughes, R. A., and Wiffen, P. J. (2014). Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst. Rev. 2014:CD007115. doi: 10.1002/14651858.CD007115.pub3
Marcinkiewcz, C. A., M’zzone, C. M., D’Agostino, G., Halladay, L. R., Hardaway, J. A., DiBerto, J. F., et al. (2016). Serotonin engages an anxiety and fear-promoting circuit in the extended amygdala. Nature 537, 97–101. doi: 10.1038/nature19318
Matheus, M. G., De-Lacerda, J. C., and Guimarães, F. S. (1997). Behavioral effects of “vehicle” microinjected into the dorsal periaqueductal grey of rats tested in the elevated plus maze. Brazil. J. Med. Biol. Res. 30, 61–64. doi: 10.1590/S0100-879X1997000100009
Matias, M., Silvestre, S., Falcão, A., and Alves, G. (2018). Considerations and pitfalls in selecting the drug vehicles for evaluation of new drug candidates: focus on in vivo pharmaco-toxicological assays based on the rotarod performance test. J. Pharm. Pharm. Sci. 21, 110–118. doi: 10.18433/jpps29656
Ni, Y., Feng, Y., Shen, D., Chen, M., Zhu, X., Zhou, Q., et al. (2022). Anti-IgLON5 antibodies cause progressive behavioral and neuropathological changes in mice. J. Neuroinflamm. 19:140. doi: 10.1186/s12974-022-02520-z
Pain (1979). Pain terms: a list with definitions and notes on usage. Recommended by the IASP subcommittee on taxonomy. Pain 6, 247–252. doi: 10.1016/0304-3959(79)90046-0
Paredes, S., Cantillo, S., Candido, K. D., and Knezevic, N. N. (2019). An association of serotonin with pain disorders and its modulation by estrogens. Int. J. Mol. Sci. 20:5729.
Sellmeijer, J., Mathis, V., Hugel, S., Li, X. H., Song, Q., Chen, Q. Y., et al. (2018). Hyperactivity of anterior cingulate cortex areas 24a/24b drives chronic pain-induced anxiodepressive-like consequences. J. Neurosci. 38, 3102–3115.
Shackman, A. J., Salomons, T. V., Slagter, H. A., Fox, A. S., Winter, J. J., and Davidson, R. J. (2011). The integration of negative affect, pain and cognitive control in the cingulate cortex. Nat. Rev. Neurosci. 12, 154–167. doi: 10.1523/JNEUROSCI.3195-17.2018
Slee, A., Nazareth, I., Bondaronek, P., Liu, Y., Cheng, Z., and Freemantle, N. (2019). Pharmacological treatments for generalized anxiety disorder: a systematic review and network meta-analysis. Lancet 393, 768–777. doi: 10.1038/nrn2994
Tian, Z., Yamanaka, M., Bernabucci, M., Zhao, M.-G., and Zhuo, M. (2017). Characterization of serotonin-induced inhibition of excitatory synaptic transmission in the anterior cingulate cortex. Mol. Brain 10:21. doi: 10.1016/S0140-6736(18)31793-8
Tsang, A., Von Korff, M., Lee, S., Alonso, J., Karam, E., Angermeyer, M. C., et al. (2008). Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J. Pain 9, 883–891. doi: 10.1186/s13041-017-0303-1
Velly, A. M., and Mohi, S. (2018). Epidemiology of pain and relation to psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 87, 159–167. doi: 10.1016/j.jpain.2008.05.005
Wang, G. Q., Cen, C., Li, C., Cao, S., Wang, N., Zhou, Z., et al. (2015). Deactivation of excitatory neurons in the prelimbic cortex via Cdk5 promotes pain sensation and anxiety. Nat. Commun. 6:7660. doi: 10.1016/j.pnpbp.2017.05.012
Zhu, X., Tang, H. D., Dong, W. Y., Kang, F., Liu, A., Mao, Y., et al. (2021). Distinct thalamocortical circuits underlie allodynia induced by tissue injury and by depression-like states. Nat. Neurosci. 24, 542–553. doi: 10.1038/ncomms8660